AAVANTIBIO

Biological treatments, namely, biological preparations, for use for clinical, medicinal and the therapeutic treatment of Friedreich's Ataxia and genetic disorders; biological preparations for the treatment of Friedreich's Ataxia and genetic disorders; Biospecific reagents for medical use, for use in immunotherapy for the treatment of Friedreich's Ataxia and genetic disorders; Biological preparations for use in immunotherapy for the treatment of Friedreich's Ataxia and genetic disorders; Biological preparations, namely, biological drugs in the nature of gene therapy products for use for clinical, medicinal and therapeutic treatment of Friedreich's Ataxia; biological preparations, namely, biological drugs in the nature of gene therapy products for treatment of genetic diseases and Friedreich's Ataxia; biological preparations, namely, biological drugs in the nature of gene therapy products for use in treating Friedreich's Ataxia and autoimmunity disorders and diseases; biological preparations, namely, gene therapy products in the nature of therapeutic pharmaceuticals for the treatment of Friedreich's Ataxia, autoimmune, immune system diseases and disorders; pharmaceutical preparations for human use for the treatment of Friedreich's Ataxia; Therapeutic pharmaceutical preparations and medical diagnostic agents and preparations for use in therapies for Friedreich's Ataxia and autoimmunity, all of the foregoing for medical use; Therapeutic pharmaceutical preparations and diagnostic agents, preparations and substances for medical purposes for targeting application to immunotherapies and therapeutic and diagnostic agents